Deep Vein Thrombosis (DVT) — Clinical Documentation Guide (2026)

🔍 Definition

Deep vein thrombosis (DVT) is the formation of a blood clot (thrombus) within a deep vein, most commonly in the lower extremities — the femoral, popliteal, iliac, tibial, or peroneal veins — but also occurring in the upper extremities (brachial, radial, ulnar, axillary, subclavian, internal jugular veins) and less commonly in other sites (vena cava, renal vein, hepatic vein, cerebral sinuses). DVT is a major component of venous thromboembolism (VTE), the other being pulmonary embolism (PE), which occurs when a thrombus dislodges and migrates to the pulmonary vasculature.

The condition is classified as acute (new thrombus, typically within 4 weeks of onset) or chronic (post-thrombotic, residual thrombus >4 weeks, or evidence of chronic venous changes). This acute vs. chronic distinction drives ICD-10-CM code assignment and has direct implications for HCC risk adjustment and clinical management.

Globally, DVT affects an estimated 1–2 per 1,000 persons annually, according to CDC VTE data. In hospitalized patients, untreated DVT carries a risk of PE of approximately 40–50%, making accurate documentation and timely coding critical for both patient safety outcomes and appropriate reimbursement.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

DVT is notoriously variable in presentation; up to 50% of cases are asymptomatic or minimally symptomatic. When present, classic findings include:

• Unilateral leg swelling (edema, increased limb circumference)
• Pain or tenderness along the course of the deep vein, often exacerbated by walking or dorsiflexion (Homans’ sign — low specificity, rarely documented)
• Erythema or skin warmth over the affected limb
• Skin discoloration — cyanosis (phlegmasia cerulea dolens in massive DVT) or pallor/blanching (phlegmasia alba dolens)
• Dilated superficial veins (collateral vessel prominence)
• Pitting edema distal to obstruction

Upper extremity DVT may present with arm swelling, cyanosis, heaviness, or Paget-Schroetter syndrome (effort thrombosis in athletes/manual workers following strenuous use). Catheter-related upper extremity DVT is often asymptomatic and identified incidentally on imaging.

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

The deep venous system of the lower extremity consists of paired veins accompanying the major arteries: the anterior tibial, posterior tibial, and peroneal (fibular) veins (forming the calf/distal DVT vessels), which drain into the popliteal vein behind the knee. The popliteal vein ascends to become the femoral vein (in the adductor canal and femoral triangle), then joins the deep femoral vein to form the common femoral vein, which drains into the external iliac and common iliac veins, ultimately entering the inferior vena cava.

DVT pathogenesis is classically explained by Virchow’s Triad — three interacting factors:

• Venous stasis (immobility, prolonged bed rest, long-haul travel, heart failure, obesity, paralysis)
• Endothelial injury (trauma, surgery, central venous catheters, prior DVT, vasculitis)
• Hypercoagulability (inherited thrombophilias — Factor V Leiden mutation [D68.51], prothrombin G20210A mutation [D68.52], antiphospholipid syndrome [D68.61]; acquired — malignancy, pregnancy, OCP use, inflammatory disease, heparin-induced thrombocytopenia)

Once a thrombus forms, it can propagate proximally (distal to proximal extension, increasing PE risk), embolize to the pulmonary arteries (PE — see separate CDG), or undergo fibrinolysis (spontaneous resolution) or organization (becoming chronic/fibrotic). Chronic thrombus damages venous valves, causing retrograde reflux, ambulatory venous hypertension, and ultimately post-thrombotic syndrome (PTS) — coded to I87.0xx.

The upper extremity deep venous system includes the radial, ulnar, brachial, axillary, subclavian, and internal jugular veins. Upper extremity DVT (UE-DVT) represents approximately 4–10% of all DVT cases and is increasingly catheter-related (central venous catheters, peripherally inserted central catheters [PICCs]).

💊 Medication Impact / Treatment

Anticoagulation is the cornerstone of DVT treatment. Drug selection affects coding and HCPCS billing:

• Initial/parenteral anticoagulation: Unfractionated heparin (UFH) IV infusion; Low-molecular-weight heparins (LMWH) — enoxaparin (Lovenox, J1650), dalteparin (Fragmin, J1645), fondaparinux (Arixtra, J1652)
• Oral anticoagulation (DOACs — Direct Oral Anticoagulants): Rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), edoxaban (Savaysa) — reported via NDC on Medicare Part D claims
• Vitamin K antagonist: Warfarin (Coumadin) — oral, Part D NDC; requires INR monitoring
• Thrombolytics: Alteplase (tPA, J2997) — catheter-directed or systemic; reserved for massive/limb-threatening DVT (phlegmasia cerulea dolens), PE with hemodynamic instability
• Compression therapy: Graduated compression stockings — reduces post-thrombotic syndrome risk
• IVC filter placement: CPT 37193 — reserved for patients with anticoagulation contraindication or recurrent PE
• Mechanical thrombectomy: CPT 37187/37188 — catheter-directed mechanical thrombectomy for extensive proximal DVT

Documentation of anticoagulation therapy triggers the additional code Z79.01 (long-term use of anticoagulants) when the anticoagulant is prescribed for ongoing use beyond the acute episode. This code is reportable for both inpatient and outpatient encounters per FY2026 ICD-10-CM Official Guidelines, Section I.C.21.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

Per the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (CMS), the following rules apply to DVT coding:

Acute vs. Chronic DVT

The acute vs. chronic distinction is clinically and codologically critical. Acute DVT (I82.4xx lower extremity; I82.6xx upper extremity) represents a new or recently formed thrombus — typically within the first 4 weeks of onset. Chronic DVT (I82.5xx lower extremity; I82.7xx upper extremity) represents a persistent or residual thrombus beyond 4 weeks, or imaging findings consistent with organized/chronic thrombus (echogenic, non-occlusive, with venous wall fibrosis). When documentation is ambiguous, query the provider — do not default without clinical basis.

Laterality — 5th and 6th Characters

ICD-10-CM uses the following laterality values as the final character(s) for lower extremity DVT codes:

• 1 = Right side
• 2 = Left side
• 3 = Bilateral
• 9 = Unspecified side

Coders should not default to “unspecified” (9) when laterality is documented. Query the provider or reference the duplex/CT report to determine which extremity/side is affected.

Concurrent DVT and PE

When DVT and PE are both documented, assign codes for both: the PE code (I26.xx — see PE CDG) and the DVT code (I82.4xx or I82.6xx). Per official guidelines, sequence the condition that prompted the encounter as the principal diagnosis in the inpatient setting (typically PE if that was the principal reason for admission).

Post-Thrombotic Syndrome (PTS)

When a patient with a history of DVT develops chronic venous insufficiency, stasis dermatitis, edema, or ulceration attributable to prior DVT, assign the appropriate I87.0xx code (post-thrombotic syndrome) — not the active DVT code. See the Venous Stasis/Chronic Venous Insufficiency CDG for full I87.0xx coding guidance.

Personal History of DVT (Resolved)

Z86.718 (personal history of other venous thrombosis and embolism) is used when the DVT has completely resolved and the patient is not currently anticoagulated for an active DVT. This code does NOT map to an HCC and carries no RAF weight — appropriate coding prevents risk score inflation from historical codes assigned to resolved conditions.

Thrombophilia as an Underlying Cause

When DVT occurs in a patient with documented thrombophilia (inherited or acquired), the thrombophilia should be coded as an additional diagnosis (D68.5x, D68.6x). Per Official Guidelines, conditions that affect treatment and management should be captured. Thrombophilia directly impacts anticoagulation duration decisions and prophylaxis planning.

Guideline Citations

• FY2026 ICD-10-CM Official Guidelines — CMS.gov
• ICD-10-CM Browser — CDC NCHS

🔢 ICD-10-CM Code Set (FY2026)

Lower Extremity — Acute DVT (I82.4xx)

Lower Extremity — Chronic DVT (I82.5xx)

Upper Extremity DVT (I82.6xx Acute; I82.7xx Chronic)

Other Vein Thrombosis

Related Additional Codes

🔎 Indexing

In the ICD-10-CM Alphabetical Index, DVT is indexed under multiple main terms:

• Thrombosis, thrombotic → vein → femoral (deep) → acute → I82.411/I82.412
• Deep vein thrombosis → see Thrombosis, vein
• DVT → see Thrombosis, vein, deep
• Thrombosis, thrombotic → vein → popliteal → I82.431/I82.432
Thrombosis, thrombotic → vein → iliac (common/external/internal) → I82.421/I82.422
• Thrombosis, thrombotic → vein → tibial → I82.441/I82.442
• Thrombosis, thrombotic → vein → axillary → I82.A11/I82.A12
• Thrombosis, thrombotic → vein → subclavian → I82.B11/I82.B12
• Budd-Chiari syndrome → I82.0
• Thrombophlebitis → migrans → I82.1
• Post-thrombotic syndrome → I87.0xx
• History (personal) → thrombosis → venous → Z86.718

🏥 CPT (2026)

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic advisories are relevant to DVT coding and should be referenced during audits and provider education:

• Superficial femoral vein — deep vein: Coding Clinic has affirmed that despite its name, the superficial femoral vein is anatomically a deep vein and should be coded as DVT of the femoral vein (I82.41x), not as superficial thrombophlebitis.
• Acute vs. chronic DVT: Coders should not assign “chronic” DVT without explicit provider documentation; do not infer chronicity from imaging alone without clinical confirmation. When uncertain, query the provider.
• DVT with concurrent PE: Assign codes for both the DVT and PE. The principal diagnosis for inpatient admission should reflect the condition that prompted admission (typically PE). Both conditions are separately reported.
• Post-thrombotic syndrome (I87.0xx): Code Clinic guidance specifies that I87.0xx codes are only appropriate when the provider explicitly documents post-thrombotic syndrome or its equivalent; do not infer from “chronic venous insufficiency after DVT” without a provider link.
• Incidental catheter-related upper extremity DVT: When upper extremity DVT is identified incidentally (e.g., on chest CT for PE evaluation), assign the appropriate I82.6xx code as an additional code if the provider documents the finding. Incidental findings that meet the definition of a reportable diagnosis (affect management, require additional workup or treatment) should be coded per Official Guidelines Section III.
• Bilateral DVT (I82.4X3): When both extremities are involved simultaneously, the bilateral (3) character is preferred over coding two separate unilateral codes, per Coding Clinic and the ICD-10-CM instructional notes.

💰 HCC / Risk Adjustment (v28)

✍️ CDI Query Templates

🧑‍⚕️ Treatments (Clinical)

Evidence-based DVT management follows guidelines from the American Society of Hematology (ASH) 2020 VTE Guidelines and the American College of Chest Physicians (ACCP) CHEST Guidelines:

Anticoagulation — First-Line Treatment

• DOACs (preferred for most patients): Apixaban 10 mg BID × 7 days → 5 mg BID; Rivaroxaban 15 mg BID × 21 days → 20 mg QD; Dabigatran (after 5–10 days parenteral); Edoxaban (after 5–10 days parenteral)
• LMWH + warfarin: Bridge therapy; used in pregnancy (LMWH preferred), cancer-associated thrombosis (LMWH preferred per CLOT/SELECT-D trials), and with certain drug interactions
• Duration: 3 months minimum for provoked DVT (reversible risk factor); extended/indefinite therapy for unprovoked DVT, cancer-associated DVT, or recurrent DVT. Thrombophilia type influences duration.

Invasive / Interventional Management

• Catheter-directed thrombolysis (CDT): For iliofemoral DVT with high thrombus burden; reduces post-thrombotic syndrome; alteplase infusion via multi-sidehole catheter
• Pharmacomechanical catheter-directed thrombolysis (PCDT): Combines mechanical disruption with thrombolytic infusion
• Mechanical thrombectomy (CPT 37187/37188): For acute massive DVT, phlegmasia cerulea dolens with threatened limb
• IVC filter (CPT 37191): Indicated when anticoagulation is absolutely contraindicated (active major bleeding, recent neurosurgery) or for recurrent PE despite adequate anticoagulation. Retrievable filters preferred — removal should be attempted when anticoagulation becomes feasible (CPT 37193)

Compression Therapy & Rehabilitation

• Graduated compression stockings (30–40 mmHg) reduce post-thrombotic syndrome development and ambulatory edema
• Early ambulation with adequate anticoagulation is encouraged; bed rest is no longer routinely recommended per ASH guidelines

Special Populations

• Pregnancy: LMWH (enoxaparin, dalteparin) throughout pregnancy; DOACs and warfarin contraindicated in first trimester
• Cancer-associated DVT: LMWH or edoxaban/rivaroxaban preferred (HOKUSAI/SELECT-D/ADAM VTE trials); duration = cancer-active period or indefinite
• HIT (heparin-induced thrombocytopenia): Stop all heparin products; use argatroban, bivalirudin, or fondaparinux; eventual warfarin transition

🎓 Patient Education / Summary

Patient education for DVT focuses on medication adherence, recognition of complications (PE warning signs), and prevention of recurrence:

Key Education Points

• Medication adherence: Never stop blood thinners without consulting your provider — even if you feel better. DVT can recur, and PE is a life-threatening complication. If prescribed a DOAC (rivaroxaban, apixaban), take exactly as directed — some require twice-daily dosing initially.
• Warning signs of PE: Seek emergency care immediately for sudden chest pain, shortness of breath, rapid heart rate, coughing up blood, or lightheadedness — these may indicate the clot has traveled to the lungs.
• Activity and mobility: Stay active as tolerated. Avoid prolonged immobility. For long trips (>4 hours), stand, walk, and perform calf exercises every 1–2 hours. Stay well hydrated.
• Compression stockings: Wear prescribed compression stockings daily during waking hours to reduce swelling and prevent post-thrombotic syndrome.
• Bleeding precautions: Blood thinners increase bleeding risk. Report unusual bruising, prolonged bleeding from cuts, blood in urine/stool, or severe headaches to your provider.
• Drug and food interactions: Warfarin (Coumadin) interacts with many medications and foods high in Vitamin K (leafy greens). Maintain consistent dietary intake and report all new medications. DOACs have fewer interactions but still interact with certain antifungals, anticonvulsants, and other drugs.
• Follow-up: Keep all scheduled follow-up appointments for repeat imaging (if ordered) and INR monitoring (if on warfarin). Inform all healthcare providers that you are on anticoagulant therapy before any procedures.

For more information, visit CDC VTE Resources and the American Society of Hematology Patient Blood Clot Education.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)